Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm)

重组全人源抗PCSK9单克隆抗体（天士力）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm)
Drug Alias NameB-1655B1655
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTianjin Tasly Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTianjin Tasly Pharmaceutical Co LtdTasly Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A